MLTX DEADLINE: Rosen urges MoonLake Immunotherapeutics investors to act before December 15, 2025

The Rosen Law Firm — a top‑ranked global investor‑rights law firm — has issued a reminder to all who purchased common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025 (the “Class Period”) that December 15, 2025 is the deadline to file for lead‑plaintiff status in the ongoing securities class‑action lawsuit. If you bought MoonLake stock during that period, you may be eligible for compensation — under a contingency fee arrangement, meaning no out-of-pocket costs. To join the case or attempt to become lead plaintiff, investors must timely submit the required motion by December 15. Interested parties can fill out the form on the Rosen Law Firm’s website or contact attorney Phillip Kim for more information. The lawsuit alleges that MoonLake misled investors by making false or misleading statements about the difference between the drug candidate sonelokimab’s “Nanobody” structure (SLK) and traditional monoclonal antibodies — specifically claiming superior tissue penetration, efficacy and differentiation from competitors. When later data emerged showing these claims were unfounded, the company’s share price plummeted, triggering substantial losses for shareholders. If you believe you qualify, now’s the time to secure legal counsel and act — or risk losing the opportunity to participate. #MoonLake #MLTX #SecuritiesFraud #InvestorAlert #SlimScan #GrowthStocks #CANSLIM